ADVERTISEMENT

Paraguay

Henlius Partners With Mabxience On Trastuzumab

Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.

Joint Price Negotiations Move Ahead In Latin America

Latin American countries are continuing to pursue a strategy of jointly negotiating medicine prices to get a better deal on expensive medicines. However, manufacturers have expressed doubt that this is the best way forward.

Mercosur Bets On Joint Pricing Negotiations And Procurement For Lower Prices, But Slams Hep C Companies

Countries in South America have negotiated lower prices for the immunosuppressant tacrolimus and have their sights on high-cost oncology treatments. However, they have slammed companies selling new hepatitis C treatments for their inflexibility.

EU Under Fire Again For Pursuing Investor-State Dispute Settlement-like Mechanisms

The EU is once again facing criticism for its pursuit of investor-state dispute settlement-like mechanisms.

IPR-Enhancing EU-Mercosur Trade Talks Set To Resume After Stalling

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

IPR-Enhancing EU-Mercosur Trade Talks Set To Resume After Stalling

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

<em>Silka </em>Marketer Scratches Monograph Claim Itch In NAD Review

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

<em>Silka </em>Marketer Scratches Monograph Claim Itch In NAD Review

In response to a National Advertising Division inquiry on efficacy claims challenged by Bayer Healthcare, the US subsidiary of Mexican firm Genomma Lab Corp. said some claims for its Silka athlete's foot treatment were discontinued "but continued to air due to a miscommunication in its marketing department."

Weekly Trademark Review Jan. 6, 2015

OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.

Weekly Trademark Review Jan. 6, 2015

OTC drug, personal care product and nutritional supplement trademark filings compiled by “The Tan Sheet” from Official Gazette of the U.S. Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps; and Class 5 – Pharmaceuticals.